Carly Helfand on Muck Rack

Carly Helfand

Verified
Washington, D.C.
Reporter and Editor — Fierce Pharma

Reporter/editor for @FiercePharma and FiercePharmaMarketing; Chicago native; intent traveler; hockey fan; Irish fiddler; comma police.

Search Tweets

Twitter Feed

@CarlyHFierce — 2,118 followers, 3,975 tweets

Jul 19, 2017

For Biogen's Spinraza launch, things are looking up on the coverage front: analyst  http://bit.ly/2vjNAaY  $BIIB #pharma #marketing

Jul 19, 2017

J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances:  http://bit.ly/2vDbEVR  $JNJ $LLY #pharma

Jul 19, 2017

Gilead gets its OK for blockbuster hopeful Vosevi, but will 12-week dosing give it trouble?  http://bit.ly/2vCP0Nj  $GILD $ABBV #pharma

Jul 19, 2017

#ICMYI: Remicade is ready to fend off biosim No. 2, $JNJ execs say amid Q2 revenue miss  http://bit.ly/2vBPZgQ  $PFE #pharma #marketing

Show more